AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver

Core Insights - AbbVie Inc. announced that emraclidine failed in both phase 2 trials for schizophrenia patients, which is considered a shocking outcome in the biotech sector [2]. Company Summary - AbbVie Inc. (NYSE: ABBV) faced a significant setback with the failure of emraclidine in clinical trials, which may impact its future growth prospects and investor sentiment [2].